AI model revolutionizes dementia diagnosis with high accuracy across multiple data sources

The team at Sea­port Ther­a­peu­tics, a Boston neu­ropsy­chi­a­try biotech, is hav­ing a good fall sea­son. Sea­port said Mon­day it has pieced to­geth­er $225 mil­lion from

Ma­chine learn­ing and AI have sparked a trans­for­ma­tion in drug dis­cov­ery, but crack­ing the bi­ol­o­gy is still para­mount. That’s the think­ing be­hind a new col­lab­o­ra­tion